From vibrators to penis size to squirting, these are the topics sex educators say people secretly want to know more about.

The new prostate cancer spit test reduced the number of false positive results and picked up a higher proportion of ...

Search for other works by this author on: 1Ontario Institute for Cancer Research, Toronto, Canada. 8Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 9Australian Prostate ...

Cystoprostatectomy is a type of surgery to treat bladder cancer in men. It involves removing both the bladder (called a cystectomy) and the prostate gland (prostatectomy) in men who have cancer ...

A person with a prostate can achieve an orgasm using a number ... Reach your perineum or anus with your finger. To do this with a partner: Lie face down with your arms at your sides and legs ...

Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis - Beyond the Abstract ...

Cancer can be a cause of low hemoglobin (anemia), and is often seen with cancer types that include leukemia, breast cancer, colon cancer, and prostate cancer. Chemotherapy and radiation treatments for ...

BPH is more common as men age. According to the Prostate Cancer Foundation, about 20% of men in their 50s have an enlarged prostate, 60% of men in their 60s, and 70% of men by age 70. Let’s ...

AN MSP has described NHS Ayrshire and Arran waiting times for prostate cancer treatment as a "timebomb". The 62-day standard states that 95 per cent of eligible patients should wait no longer than 62 ...

“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...